Trek Financial’s Dyne Therapeutics DYN Stock Holding History

Trek Financial’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-99,959	Closed	-$3.53M	–	409
2024 Q2	$3.53M	Buy	+99,959	New	+$2.9M	0.28%	89

Other funds holding DYN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Trek Financial's DYN Position: Q3 2024 in Review

Trek Financial sold out of Dyne Therapeutics (DYN) in Q3 2024, closing a stake of 99,959 shares — an estimated $3.53M sold.

Trek Financial first reported a position in DYN in Q2 2024 and held it in 1 quarter. The position peaked at $3.53M in Q2 2024. 200 funds tracked by Wall St. Rank hold DYN as of Q3 2024.

Trek Financial reported no remaining Dyne Therapeutics position as of Q3 2024 after selling out during the quarter.
Trek Financial sold 99,959 Dyne Therapeutics shares in Q3 2024, an estimated $3.53M.
Trek Financial first reported a position in Dyne Therapeutics in Q2 2024 and held it in 1 quarter.
Trek Financial's Dyne Therapeutics position peaked at $3.53M in Q2 2024.
200 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2024.

Based on Trek Financial's 13F filing for Q3 2024, filed 14 Nov 2024.